A5008114224- Lung Cancer Treatments and Mutations
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- Fibroblast Growth Factor Research
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Gastrointestinal Tumor Research and Treatment
- SARS-CoV-2 detection and testing
- Infection Control and Ventilation
- Ovarian cancer diagnosis and treatment
- Hair Growth and Disorders
- Ferroptosis and cancer prognosis
- IgG4-Related and Inflammatory Diseases
- Cancer therapeutics and mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Global Cancer Incidence and Screening
- Antiplatelet Therapy and Cardiovascular Diseases
- Chemotherapy-related skin toxicity
LMU Klinikum
2025
Ludwig-Maximilians-Universität München
2025
University Hospital of Zurich
2024
Sigmund Freud University Vienna
2020-2023
Vienna BioCenter Core Facilities
2021
Vienna Biocenter
2021
Sigmund Freud University
2020-2021
The COVID-19 pandemic has demonstrated the need for massively-parallel, cost-effective tests monitoring viral spread. Here we present SARSeq, saliva analysis by RNA sequencing, a method to detect SARS-CoV-2 and other respiratory viruses on tens of thousands samples in parallel. SARSeq relies next generation sequencing multiple amplicons generated multiplexed RT-PCR reaction. Two-dimensional, unique dual indexing, using four indices per sample, enables unambiguous scalable assignment reads...
Abstract Next generation sequencing (NGS) together with protein expression analysis is back bone of molecularly targeted therapy in precision medicine. Our retrospective study shows our experience NGS 324 genes combination patients advanced breast cancer (aBC). The primary purpose was to analyze the prevalence individual genetic alterations combined define potential targets for an individualized therapy. Between April 2018 and September 2019, 41 aBC were offered a test. test used detect...
39 Background: To assess the prognostic value of post-therapy [ 177 Lu]Lu-PSMA (LuPSMA)-SPECT/CT by visual RECIP 1.0 during LuPSMA radioligand therapy and to develop an evidence-based clinical protocol monitor efficacy LuPSMA. Methods: Patients who received between April 2019 November 2023 underwent at least two LuPSMA-SPECT/CT (SPECT) were included. Three independent readers interpreted pairs baseline interim after 2 cycles for Response Evaluation Criteria In PSMA-imaging (RECIP) 1.0. The...
Ziel/Aim: Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging (RECIP) 1.0 is an evidence-based framework that used to assess the response therapy PSMA-PET/CT. Innovative approaches of 177Lu-PSMA radiopharmaceutical (RPT) extend treatment beyond currently approved 6 cycles. So far, no data are available on use RECIP post-therapeutic SPECT under extended RPT. We aimed at comparing results PET and with biochemical patients
Ziel/Aim: 177Lu-PSMA radiopharmaceutical therapy (RPT) shows favorable clinical responses in patients with metastatic castration-resistant prostate cancer (mCRPC). The kidney, an organ-at-risk, is susceptible to radiation induced damage due specific and nonspecific uptake. We seek examine if there a correlation between cumulative kidney absorbed doses the long-term toxicity after RPT.
Our objectives were to assess the prognostic value of posttherapy [177Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical protocol monitor efficacy LuPSMA. Methods: Patients with metastatic castration-resistant prostate cancer who received at least 2 cycles between April 2019 November 2023 retrospectively included in this study. Pairs baseline interim (SPECT) PSMA PET/CT (PET) images after analyzed per 1.0. Changes...
Increasing knowledge about the genomic changes underpinning cancer development and growth has led to a rapidly expanding number of individualized therapies that specifically target these in patient's tumor. Here we present case report patient with metastatic esophageal carcinoma whose tumor harbored NTRK1 gene amplification who received targeted systemic therapy larotrectinib. At initial diagnosis, presented obstruction middle esophagus, simultaneous liver lung metastases, UICC IV WHO...
Screening mammography is a widely used approach for early breast cancer detection, effectively increasing the survival rate of affected patients. According to Food and Drug Administration's Mammography Quality Standards Act Program statistics, approximately 39 million procedures are performed in United States each year. Therefore, screening among most common radiological tasks. Interpretation mammograms by specialist radiologist includes primarily review positioning quality, which key factor...
Abstract Oncologic patients are regarded as the population most at risk of developing a severe course COVID‐19 due to fact that malignant diseases and chemotherapy often weaken immune system. In face ongoing SARS‐CoV‐2 pandemic, how particular deal with this infection remains an important question. period between 15 26 April 2020, total 1227 were tested in one seven oncologic outpatient clinics for SARS‐CoV‐2, regardless symptoms, employing RT‐qPCR. Of patients, 78 (6.4%) positive...
Background Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because not yet approved first-line therapy, the presently applied to individuals that received prior therapies can have immunocompromising effects. There is a need address how treatments impact vaccine outcomes. Method Therefore, we analyzed response BioNTech/Pfizer’s anti-SARS-CoV-2 in 237 oncology outpatients, which cover broad spectrum of hematologic malignancies and solid tumors variety...
Point mutations of the fibroblast growth factor receptor (FGFR)2 in intrahepatic cholangiocarcinoma (iCC) are mainly unknown functional significance compared to FGFR2 fusions. Pemigatinib, a tyrosine kinase inhibitor, is approved for treatment with fusion/rearrangement. Although it hypothesized that may cause uncontrolled activation signaling pathway, data targeted therapies remain unclear. In vitro analyses demonstrated importance p.C382R mutation ligand-independent constitutive...
SARS-CoV-2 antibody development and immunity will be crucial for the further course of pandemic. Until now, it has been assumed that patients who are infected with develop antibodies as case other coronaviruses, like MERS-CoV SARS-CoV. In present study, we analyzed in 77 an oncologic diagnosis 26 days after positive RT-qPCR testing SARS-CoV2. anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used,...
After several years of negative phase III trials in gastric and esophageal cancer, a significant breakthrough the treatment metastatic adenocarcinomas gastroesophageal junction (GEJ) stomach (GC) is now becoming evident with emerging precision oncology implementation molecular targets tumor treatment. In addition, new generation studies such as umbrella basket are focused on these targets, which makes an early diagnosis based IHC/ISH NGS necessary. The required companion diagnostics Her2neu...
The aim of this survey was to assess the efficacy and feasibility scalp cooling (SC) in an outpatient hematological oncological center a real-world setting.We prospectively monitored cancer patients from August 2017 October 2019 receiving treatments with SC, using sensor-controlled system "DigniCap." Effectiveness defined by self-estimated hair loss < Grad 2 (<50%) according Common terminology Criteria for adverse events V4.0 or not requiring wig. Withdrawal SC on patient's demand considered...
8641 Background: Recent research suggests that loss of heterozygosity (LOH) in KEAP1/STK11 mutated lung adenocarcinoma (LUAD) may present a new immunological and biological aggressive subtype unresponsive to current standard care treatment options. Currently, there is limited data on the clinical impact LOH co-alterations real-world settings. Methods: From November 1 st , 2021, October 1st, 2023, patients with LUAD mutations detected by FoundationOne CDx any genes KEAP1, STK11, KRAS were...
Introduction We present a case report of patient with metastatic esophageal carcinoma whose tumor harbored NTRK1 gene amplification and who received targeted systemic therapy larotrectinib. At initial diagnosis, the presented tumor-obstruction middle esophagus simultaneously liver lung metastases (UICC IV). The WHO Performance Status was 3 had weight loss 20 kg over 12 weeks.
e13005 Background: Next generation sequencing (NGS) together with protein expression analysis is back bone of molecularly targeted therapy in precision medicine. The present study shows the retrospective our experience NGS using a panel 324 genes combination patients metastatic breast cancer (mBC) over last 18 months. primary objective this was to analyze prevalence individual genetic alterations combined define potential targets for an individualized therapy. Methods: We analyzed 41...
Abstract SARS-CoV-2 antibody development and immunity will be crucial for the further course of pandemic. Until now, it has been assumed that patients who were infected with develop antibodies as is case other coronaviruses, like MERS-CoV SARS-CoV. In present study, we analyzed 77 oncology 26 days after positive RT-qPCR testing SARS-CoV-2. anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) Roche (Elecsys Anti-SARS-CoV-2 immunoassay) used,...
e18750 Background: Data on SARS-CoV-2 infections in oncological patients the outpatient settings are scarce. Methods: During spread of delta variant between April 2021 and September 2021, a total 10.677 were tested for infection by RT-qPCR seven clinics Bavaria, Germany. Results: Within patient cohort, 4.960 (46.5%) suffered from malignant disease (74% solid tumors 26% hematological diseases). This group was compared with 5.717 (53.5%) without (33.1% other diseases 66.9% or disease)....